Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC148 plus platinum chemotherapy versus tislelizumab plus platinum chemotherapy as first-line treatment for advanced driver gene-negative non-squamous non-small cell lung cancer
CTR20263492Phase 3Active
- Sponsor
- RemeGen
- Start
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RC148 in non-small cell lung cancer (NSCLC), sponsored by RemeGen. Started Sep 2026; status: active.
02
Drugs
RC148
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20263492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263492.